London
· Delayed Price · Currency is GBP · Price in USD Aclaris Therapeutics Statistics
Total Valuation
LON:0H8T has a market cap or net worth of GBP 109.35 million. The enterprise value is -31.31 million.
| Market Cap | 109.35M |
| Enterprise Value | -31.31M |
Important Dates
The last earnings date was Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 108.28M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +27.19% |
| Shares Change (QoQ) | +28.42% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 67.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.95 |
| PB Ratio | 0.98 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.31 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 3.28 |
Financial Position
The company has a current ratio of 5.06, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.06 |
| Quick Ratio | 4.91 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.20 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -91.03% and return on invested capital (ROIC) is -23.19%.
| Return on Equity (ROE) | -91.03% |
| Return on Assets (ROA) | -18.20% |
| Return on Invested Capital (ROIC) | -23.19% |
| Return on Capital Employed (ROCE) | -30.68% |
| Revenue Per Employee | 218,400 |
| Profits Per Employee | -1.60M |
| Employee Count | 64 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.09% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +8.09% |
| 50-Day Moving Average | 1.42 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 52.73 |
| Average Volume (20 Days) | 3,523 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.00 |
Income Statement
In the last 12 months, LON:0H8T had revenue of GBP 13.76 million and -100.78 million in losses. Loss per share was -1.12.
| Revenue | 13.76M |
| Gross Profit | -25.30M |
| Operating Income | -41.93M |
| Pretax Income | -100.78M |
| Net Income | -100.78M |
| EBITDA | -41.79M |
| EBIT | -41.93M |
| Loss Per Share | -1.12 |
Balance Sheet
The company has 81.51 million in cash and 1.92 million in debt, giving a net cash position of 145.54 million.
| Cash & Cash Equivalents | 81.51M |
| Total Debt | 1.92M |
| Net Cash | 145.54M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 111.51M |
| Book Value Per Share | 1.03 |
| Working Capital | 67.55M |
Cash Flow
In the last 12 months, operating cash flow was -9.53 million and capital expenditures -22,446, giving a free cash flow of -9.56 million.
| Operating Cash Flow | -9.53M |
| Capital Expenditures | -22,446 |
| Free Cash Flow | -9.56M |
| FCF Per Share | n/a |
Margins
| Gross Margin | -183.84% |
| Operating Margin | -304.78% |
| Pretax Margin | -732.46% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:0H8T does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.19% |
| Shareholder Yield | n/a |
| Earnings Yield | -92.16% |
| FCF Yield | -8.74% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0H8T has an Altman Z-Score of -5.02. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.02 |
| Piotroski F-Score | n/a |